TRAF3

Across TCGA pan-cancer cohorts, TRAF3 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated TRAF3 data layer compared with 25 for mass-spec protein and 2 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher TRAF3 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated TRAF3 expression acts as an unfavorable survival marker, although some lineages such as GBM show a favorable association.

LUAD, CCRCC, and GBM are the cancer types where TRAF3 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	DFS	Tertile	III,IV	0.269	1.000	.004	13	view →
CCRCC	OS	Tertile	All	0.603	1.000	.010	4	view →
GBM	OS	Median	All	0.927	0.784	.027	3	view →
PDAC	OS	Median	IV	0.405	0.828	.038	3	view →
LSCC	DFS	Median	II,III,IV	0.873	1.000	.044	2	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

TRAF3–LUAD (DFS)

Open the LUAD breakdown →